The Cochrane Library, MEDLINE Ovid, and Embase Ovid ‐ run to April 2015

1 (Lyspro$ or Lispro$).ti,ab,ot. 2 (Lys$B28 or B28Lys$ or (lys$ adj1 B28)).ti,ab,ot. 3 (Pro$B29 or B29Pro$ or (pro$ adj1 B29)).ti,ab,ot. 4 humalog$.ti,ab,ot,tn. 5 133107‐64‐9.rn. 6 or/1‐5 7 (insulin$ adj1 aspart$).ti,ab,ot. 8 (Asp$B28 or B28Asp$ or (asp$ adj1 B28)).ti,ab,ot. 9 (Novorapid$ or Novolog$).ti,ab,ot,tn. 10 116094‐23‐6.rn. 11 or/7‐10 12 (Glulisin$ or Glulysin$).ti,ab,ot. 13 (Glu$B29 or B29Glu$ or (glu$ adj1 B29)).ti,ab,ot. 14 (Lys$B3 or B3Lys$ or (lys$ adj1 B3)).ti,ab,ot. 15 Apidra$.ti,ab,ot,tn. 16 207748‐29‐6.rn. 17 or/12‐16 18 6 or 11 or 17 19 (insulin$ adj6 (analog$ or derivat$)).ti,ab,ot. 20 ((shortacting or fastacting or rapidacting) adj6 insulin$).ti,ab,ot. 21 ((short$ or fast$ or rapid$) adj1 acting adj6 insulin$).ti,ab,ot. 22 ((novel or new) adj6 insulin$).ti,ab,ot. 23 or/19‐22 24 exp insulin/aa 25 Insulin Derivative/ or insulin aspart/ or insulin glulisine/ or insulin lispro/ or recombinant human insulin/ or short acting insulin/ or synthetic insulin/ 26 or/24‐25 27 23 or 26 28 exp Diabetes Mellitus/ 29 diabet$.ti,ab,ot. 30 mellitu$.ti,ab,ot. 31 IDDM.ti,ab,ot. 32 MODY.ti,ab,ot. 33 NIDDM.ti,ab,ot. 34 (T1DM or T2DM or ((T1 or T2) adj1 DM)).ti,ab,ot. 35 (insulin$ depend$ or insulin?depend$ or noninsulin$ or noninsulin?depend$).ti,ab,ot. 36 ((matury or late) adj onset$ adj6 diabet$).ti,ab,ot. 37 (typ$ adj6 diabet$).ti,ab,ot. 38 or/30‐37 39 exp Diabetes Insipidus/ 40 insipid$.ti,ab,ot. 41 or/39‐40 42 28 or 38 43 42 or (29 not (41 not 42)) 44 (18 or 27) and 43 45 44 use pmoz 46 44 use emed 47 44 use cctr 48 randomized controlled trial.pt. 49 controlled clinical trial.pt. 50 randomized.ab. 51 placebo.ab. 52 clinical trials as topic.sh. 53 randomly.ab. 54 trial.ti. 55 or/48‐54 56 exp animals/ not humans.sh. 57 55 not 56 58 crossover procedure/ 59 Double Blind Procedure/ 60 Randomized Controlled Trial/ 61 Single Blind Procedure/ 62 random$.ti,ab. 63 factorial$.ti,ab. 64 (crossover$ or cross‐over$).ti,ab. 65 placebo$.ti,ab. 66 (doubl$ adj blind$).ti,ab. 67 (singl$ adj blind$).ti,ab. 68 assign$.ti,ab. 69 allocat$.ti,ab. 70 volunteer$.ti,ab. 71 or/58‐70 72 45 and 57 73 46 and 71 74 47 or 72 or 73

MEDLINE Ovid ‐ run from January 2015

1. (lyspro* or lispro*).tw. 2. (lys?B28 or B28lys* or (lys* adj1 B28)).tw. 3. (pro?B29 or B29pro* or (pro* adj1 B29)).tw. 4. (humalog* or admelog or liprolog).tw. 5. ("LY 275585" or LY275585).tw. 6. or/1‐5 7. (insulin* adj1 aspart*).tw. 8. (asp*B28 or B28asp* or (asp* adj1 B28)).tw. 9. (novorapid* or novolog*).tw. 10. or/7‐9 11. (glulisin* or glulysin*).tw. 12. (glu?B29 or B29Glu* or (glu* adj1 B29)).tw. 13. (lys*B3 or B3lys* or (lys* adj1 B3)).tw. 14. apidra*.tw. 15. "HMR 1964".tw. 16. or/11‐15 17. insulin aspart/ or insulin glulisine/ or insulin lispro/ or insulin, short‐acting/ 18. ((shortacting or fastacting or rapidacting) adj3 insulin*).tw. 19. ((short* or fast* or rapid*) adj1 acting adj3 insulin*).tw. 20. or/17‐19 21. 6 or 10 or 16 or 20 22. exp Diabetes Mellitus, Type 2/ 23. diabet*.tw. 24. (MODY or NIDDM or T2D* or (T2 adj1 DM)).tw. 25. or/22‐24 26. 21 and 25 [Cochrane Handbook 2008 RCT filter ‐ sensitivity maximizing version] 27. randomized controlled trial.pt. 28. controlled clinical trial.pt. 29. randomi?ed.ab. 30. placebo.ab. 31. drug therapy.fs. 32. randomly.ab. 33. trial.ab. 34. groups.ab. 35. or/27‐31 36. exp animals/ not humans/ 37. 35 not 36 38. 26 and 37 [Wong 2006a– systematic reviews filter – SensSpec version] 39. meta analysis.mp,pt. or review.pt. or search*.tw. 40. 26 and 39 41. 38 or 40 42. limit 41 to yr="2015‐Current" 43. remove duplicates from 42

Embase Ovid ‐ run from January 2015

1. (lyspro* or lispro*).tw. 2. (lys?B28 or B28lys* or (lys* adj1 B28)).tw. 3. (pro?B29 or B29pro* or (pro* adj1 B29)).tw. 4. (humalog* or admelog or liprolog).tw. 5. ("LY 275585" or LY275585).tw. 6. or/1‐5 7. (insulin* adj1 aspart*).tw. 8. (asp*B28 or B28asp* or (asp* adj1 B28)).tw. 9. (novorapid* or novolog*).tw. 10. or/7‐9 11. (glulisin* or glulysin*).tw. 12. (glu?B29 or B29Glu* or (glu* adj1 B29)).tw. 13. (lys*B3 or B3lys* or (lys* adj1 B3)).tw. 14. apidra*.tw. 15. "HMR 1964".tw. 16. or/11‐15 17. ((shortacting or fastacting or rapidacting) adj3 insulin*).tw. 18. ((short* or fast* or rapid*) adj1 acting adj3 insulin*).tw. 19. or/17‐18 20. 6 or 10 or 16 or 19 21. non insulin dependent diabetes mellitus/ 22. diabet*.tw. 23. (MODY or NIDDM or T2D* or (T2 adj1 DM)).tw. 24. or/21‐23 25. 20 and 24 [Wong 2006b"sound treatment studies" filter – best optimization of sens. and spec. version] 26. random*.tw. or placebo*.mp. or double‐blind*.tw. 27. 25 and 26 28. (2015* or 2016* or 2017*).dc. 29. 27 and 28 30. remove duplicates from 29

Cochrane Register of Studies Online (CRSO) ‐ run 31 October 2018

1. (lyspro* or lispro*):TI,AB,KY 2. (lys?B28 or B28lys* or (lys* adj1 B28)):TI,AB,KY 3. (pro?B29 or B29pro* or (pro* adj1 B29)):TI,AB,KY 4. (humalog* or admelog or liprolog):TI,AB,KY 5. ("LY 275585" or LY275585):TI,AB,KY 6. #1 or #2 or #3 or #4 or #5 7. (insulin* adj1 aspart*):TI,AB,KY 8. (asp*B28 or B28asp* or (asp* adj1 B28)):TI,AB,KY 9. (novorapid* or novolog*):TI,AB,KY 10. #7 or #8 or #9 11. (glulisin* or glulysin*):TI,AB,KY 12. (glu?B29 or B29Glu* or (glu* adj1 B29)):TI,AB,KY 13. (lys*B3 or B3lys* or (lys* adj1 B3)):TI,AB,KY 14. apidra*:TI,AB,KY 15. "HMR 1964":TI,AB,KY 16. #11 or #12 or #13 or #14 or #15 17. MESH DESCRIPTOR Insulin Aspart 18. MESH DESCRIPTOR Insulin Glulisine 19. MESH DESCRIPTOR Insulin Lispro 20. MESH DESCRIPTOR Insulin, Short‐Acting 21. ((shortacting or fastacting or rapidacting) adj3 insulin*):TI,AB,KY 22. ((short* or fast* or rapid*) adj1 acting adj3 insulin*):TI,AB,KY 23. #17 or #18 or #19 or #20 or #21 or #22 24. #6 or #10 or #16 or #23 25. MESH DESCRIPTOR Diabetes Mellitus, Type 2 EXPLODE ALL TREES 26. diabet*:TI,AB,KY 27. (MODY or NIDDM or T2D* or (T2 adj1 DM)):TI,AB,KY 28. #25 or #26 OR #27 29. #24 and #28 30. 2015 TO 2017:YR 31. #29 AND #30

ICTRP (advanced search) ‐ run on 31 October 2018

diabet* AND lispro* OR diabet* AND lyspro* OR diabet* AND humalog* OR diabet* AND admelog* OR diabet* AND liprolog* OR diabet* AND aspart OR diabet* AND novorapid* OR diabet* AND novolog* OR diabet* AND glulisin* OR diabet* AND glulysin* OR diabet* AND apidra* OR T2D* AND lispro* OR T2D* AND lyspro* OR T2D* AND humalog* OR T2D* AND admelog* OR T2D* AND liprolog* OR T2D* AND aspart OR T2D* AND novorapid* OR T2D* AND novolog* OR T2D* AND glulisin* OR T2D* AND glulysin* OR T2D* AND apidra*

ClinicalTrials.gov (expert search) ‐ run on 31 October 2018

(lyspro OR lispro OR humalog OR admelog OR liprolog OR "LY 275585" OR "LY275585" OR aspart OR novorapid OR novolog OR glulisine OR glulisin OR glulysine OR apidra OR "HMR 1964" OR "short acting insulin" OR "fast acting insulin" OR "rapid acting insulin") [TREATMENT] AND(diabetes OR diabetics OR MODY OR NIDDM OR T2D OR T2DM OR "T2 DM" ) [DISEASE] AND EXACT "Interventional" [STUDY‐TYPES]